The ILLUMINA Study. (ILLUMINA)

计划入组 100 人 · 首次发布于 2018 年 4 月 27 日

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

计划入组 75 人 · 首次发布于 2023 年 10 月 19 日

Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

计划入组 763 人 · 首次发布于 2020 年 9 月 23 日

PHLYT™ Oncology Program (Casma Therapeutics)

ENKASTIM™

Covax-19™

Illumina

United States

VERINATA HEALTH, INC.

United States

Race Oncology

Belgium

Velsera Technology Drives Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight Oncology Comprehensive IVD

Illumina Secures CMS Reimbursement for TruSight Oncology Comprehensive Test at $2,989.55

FDA Approves Illumina's TruSight Oncology Comprehensive IVD with Velsera Technology